Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Provided by GlobeNewswire Aug 19, 2025, 1:05:00 PM ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals has secured conditional marketing authorization for Rezdiffra, its treatment for a serious liver condition, from regulators in Europe. The biopharmaceutical company said ...

In other recent news, Madrigal Pharmaceuticals reported impressive second-quarter earnings, with Rezdiffra sales reaching $212.8 million, a 55% increase from the previous quarter.

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients.